10.85
-0.52 (-4.57%)
| Previous Close | 11.37 |
| Open | 11.30 |
| Volume | 318,913 |
| Avg. Volume (3M) | 1,118,456 |
| Market Cap | 483,457,568 |
| Price / Earnings (Forward) | 12.82 |
| Price / Sales | 779.63 |
| Price / Book | 1.50 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2025 |
| Operating Margin (TTM) | -11,831.05% |
| Diluted EPS (TTM) | -1.78 |
| Quarterly Revenue Growth (YOY) | -30.90% |
| Total Debt/Equity (MRQ) | 6.25% |
| Current Ratio (MRQ) | 32.19 |
| Operating Cash Flow (TTM) | -74.10 M |
| Levered Free Cash Flow (TTM) | -25.69 M |
| Return on Assets (TTM) | -17.20% |
| Return on Equity (TTM) | -30.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Septerna, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 5.0 |
| Average | 2.38 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 2.64% |
| % Held by Institutions | 105.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Catalio Capital Management, Lp | 31 Mar 2025 | 1,024,245 |
| 52 Weeks Range | ||
| Median | 26.00 (139.63%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Aug 2025 | 26.00 (139.63%) | Buy | 11.70 |
| 23 Jun 2025 | 26.00 (139.63%) | Buy | 10.53 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KLEIN UWE | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KLEIN UWE | Officer | 18 Aug 2025 | Option execute | 23,008 | - | - |
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Septerna to Participate in Upcoming Investor Conferences |
| 21 Aug 2025 | Announcement | Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases |
| 11 Aug 2025 | Announcement | Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |